<h3>Purpose/Objective(s)</h3> Radiation therapy is integral to the treatment of glioblastomas. Radiation induced scalp toxicity, however, is common and can negatively impact patients' quality of life. Volumetric modulated radiation therapy (VMAT) can optimize dose to organs at risk. We hypothesize that scalp-sparing VMAT (SSV) can significantly reduce undesirable dose to the scalp without compromising target dose. In this study, we evaluate the dosimetric feasibility and benefit of SSV for patients with newly diagnosed glioblastomas (GBM). <h3>Materials/Methods</h3> This is a retrospective study of GBM patients who received radiation treatment at our institution with conventional VMAT without scalp-sparing optimization. We contoured the scalp for these patients, which was defined as a 5 mm ring structure beneath the skin, above the foramen magnum. We replanned these patients using non-coplanar SSV techniques. Dosimetric data for scalp, target, and critical normal structure were collected and compared. <h3>Results</h3> 20 patients with newly diagnosed GBM were selected for this study. All patients received a total radiation dose of 60 Gy in 30 fractions. 10 patients received 60 Gy in 30 fractions in a single-course. The rest received radiation in a split-course, with 46 Gy in 23 fractions to an initial volume followed by 14 Gy in 7 fractions to a cone-down volume, for a combined dose of 60 Gy in 30 fractions. New VMAT plans were generated after adding scalp as an organ at risk. Median scalp volume was 410 cc (range: 377-443 cc). With SSV, there was no significant reduction in maximum scalp dose. However, SSV significantly reduced mean scalp dose, doses received by 20cc and 30 cc of the scalp, and volumes of the scalp receiving 30 Gy, 40 Gy and 50 Gy. Median reduction in mean scalp dose was 21.4% (range: 5.0–39.9%), from 14.6 Gy to 10.9 Gy. Median reduction in 20 cc scalp dose was 33.9% (range: 2.7–36.9%), from 43.9 Gy to 33.9 Gy, and 30 cc scalp dose was 24.2% (range: 5.3-39.5%), from 36.6 Gy to 28.1 Gy. There were significant reductions in the volumes of scalp receiving 30 Gy, 40 Gy, and 50 Gy as well. There were no significant differences in the doses of target, brainstem, and optic nerves between non-SSV and SSV plans. <h3>Conclusion</h3> Scalp-sparing VMAT is a feasible technique and can significantly reduce scalp radiation dose without compromising target coverage or critical normal structure constraints. This may lead to reduced acute and late radiation toxicity to the scalp. A prospective trial evaluating the clinical benefit of this technique is ongoing (NCT03251027).